Cantor Fitzgerald Reiterates Overweight Rating for Capricor Therapeutics (NASDAQ:CAPR)

Cantor Fitzgerald reiterated their overweight rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report released on Friday morning, Benzinga reports. Cantor Fitzgerald currently has a $8.00 price objective on the biotechnology company’s stock.

Several other analysts have also recently weighed in on the stock. Maxim Group reaffirmed a buy rating and issued a $12.00 target price on shares of Capricor Therapeutics in a report on Tuesday, September 17th. Oppenheimer raised their target price on shares of Capricor Therapeutics from $14.00 to $15.00 and gave the company an outperform rating in a report on Tuesday, September 17th. Finally, HC Wainwright reaffirmed a buy rating and issued a $40.00 target price on shares of Capricor Therapeutics in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Capricor Therapeutics currently has an average rating of Moderate Buy and an average price target of $20.00.

Capricor Therapeutics Stock Performance

NASDAQ CAPR opened at $5.97 on Friday. The firm has a 50 day simple moving average of $4.39 and a 200-day simple moving average of $5.19. Capricor Therapeutics has a one year low of $2.68 and a one year high of $7.28. The firm has a market cap of $190.91 million, a price-to-earnings ratio of -6.86 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The business had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. Equities analysts predict that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics during the first quarter worth approximately $40,000. Main Street Financial Solutions LLC raised its holdings in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares in the last quarter. Rhumbline Advisers acquired a new stake in Capricor Therapeutics during the second quarter worth approximately $147,000. Finally, Jump Financial LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth approximately $258,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.